NCT06585345View on ClinicalTrials.gov

Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell in Patients With Relapsed/Refractory Acute Leukemia

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

February 18, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

November 1, 2030

Conditions
Acute-Leukemia
Interventions
BIOLOGICAL

CD7 CAR-T cell

Split intravenous infusion of CD7 CAR-T cells \[dose escalating infusion of (1-100)x10\^6 CD7 CAR-T cells/kg\]

Trial Locations (1)

Unknown

RECRUITING

The General Hospital of Western Theater Command, Chengdu

All Listed Sponsors
collaborator

YakeBiotech Ltd.

UNKNOWN

lead

The General Hospital of Western Theater Command

OTHER